Central Serous Chorioretinopathy, Polypoidal Choroidal Vasculopathy
Conditions
Keywords
Plasminogen activator inhibitor-1, Wide angle fluorescein angiography, Choroid
Brief summary
Thrombotic biomarkers and angiographic characteristics were compared among the de novo patients of central serous chorioretinopathy (CSC), polypoidal choroidal vasculopathy (PCV) and the control.
Interventions
OTHERBlood sampling
Sampling the blood including DNA to investigate the thrombotic profile
Sponsors
Samsung Medical Center
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* CSC * neurosensory detachment in optical coherence tomography (OCT) * focal leakage in fluorescein angiography (FAG) and/or late choroidal hyperpermeability in indocyanine green angiography (ICGA) * PCV * subretinal and/or sub-retinal pigment epithelial fluid in OCT * branching vascular network and/or polyps in ICGA * Control * epiretinal membrane (ERM) * without underlying systemic, ophthalmic disease other than ERM
Exclusion criteria
* Previous history of using steroid (oral, topical) * Previous history of CSC/PCV * Previous history or evidence of intraocular inflammation including uveitis * Co-existing retinal or choroidal diseases * History of allergic reaction to fluorescein or indocyanine green dye * Underlying systemic conditions that could affect the thrombotic profiles (e.g. diabetes, hypertension, metabolic syndrome, coronary artery disease, cerebrovascular diseases, stroke, chronic renal failure, current smoker, pregnancy, sleep disorder)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Serum PAI-1 SNP genotyping in active PCV and CSC patients | Less than 1 week after initial diagnosis | Serum PAI-1 SNP(single nucleotide polymorphism) genotyping |
| Serum Fibrin degradation product in active PCV and CSC patients | Less than 1 week after initial diagnosis | Serum Fibrin degradation product (μg/mL) |
| Serum PAI-1 antigen in active PCV and CSC patients | Less than 1 week after initial diagnosis | Serum PAI-1 (plasminogen activator inhibitor-1) antigen (ng/mL) |
| Serum Fibrinogen in active PCV and CSC patients | Less than 1 week after initial diagnosis | Serum Fibrinogen (mg/dl) |
| Serum Factor VIII activity in active PCV and CSC patients | Less than 1 week after initial diagnosis | Serum Factor VIII activity (%) |
| Serum Plasminogen activity in active PCV and CSC patients | Less than 1 week after initial diagnosis | Serum Plasminogen activity (%) |
| Serum D-dimer in active PCV and CSC patients | Less than 1 week after initial diagnosis | Serum D-dimer (μg/mL(FEU)) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Characteristics of indocyanine green angiography in active PCV and CSC patients | Less than 1 week after initial diagnosis | Numbers of hyperfluorescent spots in indocyanine green angiography |
| Characteristics of fluorescein angiography in active PCV and CSC patients | Less than 1 week after initial diagnosis | Numbers of leaking points of fluorescein dye in fluorescein angiography |
Countries
South Korea
Contacts
Primary ContactSe Woong Kang, MD
Outcome results
None listed